With recent advancements in our understanding of the molecular biology of GC, targeting agents for molecular targets, such as epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF) receptor, and human epidermal growth factor receptor 2 (HER2), have been used widely to improve patient survival in the setting of recurrent and metastatic GC [2, 3], but the prognosis of patients with advanced GC remains poor. The gene discussed is VEGFA; the disease is gastric cancer.